Cuban Academy of Sciences develops vaccines for the treatment of non-small cell lung cancer- Vaxira and CIMAvax. This latest type of vaccine that can treat non-small cell lung cancer (NSCLC) has undergone phase 3 clinical validation and has a good effect on non-small cell lung cancer. It has now entered clinical applications in Cuba et Peru. In hac excitando eventus enabled investigationis pristini US Praeses Baracum Obamam LV annorum levare commercia cum visitare ban Cuba, and introduced the latest anti-cancer technology to the United States in 2015. The US Food and Drug Administration (FDA) has approved the United States to conduct a clinical trial of a lung cancer vaccine developed in Cuba, which can stimulate the lung cancer patient’s own immune system.
Quod CIMAvax?
CIMAvax-EGF is a pulmonis cancer, treatment that was developed in Cuba. It is a type of immunotherapy that harnesses the body’s immune system to fight lung cancer. In 2017, Roswell Park initiated a clinical trial involving CIMAvax. Trial is a Phase I/II study of CIMAvax-EGF in combination with the anti-PD1 checkpoint inhibitor nivolumab (Opdivo®) in patients previously treated for advanced cellula parva non-pulmonis cancer (NSCLC).
Quid opus est CIMAvax?
Progressi ab inquisitoribus apud Centrum pro immunologia molecular (CIM) in Havana, Cuba, CIMAvax-EGF typum intercludit dapibus - incrementi epidermalis (EGF) — cellulis cancri crescere opus est. Cellulas directe, cellas carcinomatas vel aliter non interficit, sed eas "famas" prohibendo EGF proprio receptori (EGFR) in cellam adnectit. Haec connexio requiritur ad cellulam crescendi et multiplicandi. Sine, cellula cancer non multiplicat ac moritur. CIMAvax impedit EGF abusione immune responsionis patientis.
A 'dapibus carrier "in triggers CIMAvax in immune ratio est producendum ad corrumpebant ibi elementorum in EGF dapibus est. Hoc depopulatur a EGF grassentur sanguine: hoc magni momenti clavem ad incrementum cancer cellulis iuste privare dominio et salvos.
More than 5,000 lung cancer patients have been treated with this unique immunotherapy, and several international studies have indicated prolonged tuberculum stabilization and improved overall survival and quality of life for patients receiving CIMAvax. CIMAvax is an approved treatment for lung cancer in Argentina, Bosnia and Herzegovina, Colombia, Cuba, Kazakhstan, Paraguay and Peru.
Quod Vaxira?
Vaxira® is a therapeutic vaccine for the treatment of non-small cell lung cancer (NSCLC). It is composed of Racotumomab and aluminum hydroxide adjuvant.
Racotumomab est anti-idiotypic Klon inducit, quae in aegris specifica potens in immune responsio glycolylated gangliosides (NeuGcGM3) praesens est in tumore cellulis. Augetur enim in aegris Vaxira® salvos NSCLC recurrentes, seu provectus gradus (Australia / II) adminicula cura optime comparari. Salute accepta profano Vaxira® tolerandus est. Certe maxime communia sunt adversa localized (administrandae locus in), levis et transiens.
Etiam ea quae sunt immunized aegris cum morbo processus in Vaxira® post emendationem in altiore salvos ut ostensum est.
formula: Tenensque lenticulam VAXIRA® se habet: MAB Racotumomab 1.00 mg Aluminium hydroxide [Al (OH) III] 3 mg, natrii tris (hydroxymethyl) aminomethane 5.00 mg sodium chloride 12.14 mg, aqua qs iniectio pro 3.40 ml. Vaxira® est immunotherapeutic agente composito ex anti-idiotypic Klon Racotumomab et Aluminii hydroxidum (AH), a late usus adjuvant. AH amplio productio elementorum et non immunogenic hapten neque. Se habet hoc sicut vectum ad iniectio site est dimisit hoc gene tardius quam a, et, simul inducit formatio granulomas se attrahunt immunocompetent cellulis antibody-sicut producendo plasma cellulis. Sit recta AH ad producendum stimulate monocytes proinflammatory cytokines T cellulis qui excitant; et ut B ad cellulam stimulate et responsionem.
Ut emeret CIMAvax et Vaxira in India?
CIMAvax and Vaxira at present are not available in India. These vaccines need to be ordered for personalized treatment. To order the medicine please WhatsApp patient details to + 91 96 1588 1588.
